The immune system is involved in the recognition and destruction of cancer cells, nevertheless tumor subclones with reduced immunogenicity, such as loss of antigen presentation, low levels of programmed death ligand-1 (PDL1) expression and IFN-γ secretion by T cells, can be selected2 avoiding immune destroy and leading to tumor growth and clinically evident disease [2, 3]. This evidence concerns the gene IFNG and neoplasm.